MedPacto Bone Disease New Drug 'MP2021' Selected for National New Drug Development Support Project

Total Support of 1.5 Billion KRW Over 2 Years

MedPacto's innovative new drug candidate for bone disease treatment, 'MP2021,' which is being developed with the goal of entering clinical Phase 1 in 2024, has been selected for the National New Drug Development Project.

[Photo by MedPacto]

On the 4th, MedPacto announced that MP2021 was finally selected as a '2023 3rd National New Drug Development Project Non-Clinical Development Stage Support Task' hosted by the Korea Drug Development Fund (KDDF). Accordingly, MedPacto will receive a total of 1.5 billion KRW in research funding over two years.

MedPacto plans to proceed with development aiming for IND approval for the subsequent clinical Phase 1 of MP2021 or technology transfer. Unlike other arthritis and bone disease treatments that inhibit inflammation or osteoclast growth factors, MP2021 not only suppresses inflammation but fundamentally blocks the formation of multinucleated osteoclasts that dissolve bone. Through this, it is the only drug that inhibits bone loss. The related market size is known to exceed 200 trillion KRW.

Regarding the efficacy of MP2021, MedPacto recently completed animal testing and presented the clinical results last month at the American College of Rheumatology meeting held in San Diego, USA. In Europe, toxicity tests for safety verification are underway, and based on this, the plan is to enter clinical Phase 1 in 2024.

A MedPacto official stated, "The selection of MP2021’s non-clinical project is a result of recognition of the company’s technological achievements and development capabilities," adding, "Based on extensive clinical experience with Bactosertib, we will accelerate the speed of MP2021’s entry into clinical Phase 1."